BIND-014
BIND-014 is a targeted polymeric nanoparticle,[1] and is an investigational therapeutic drug in phase 2 clinical trials for various cancers,[2] e.g. metastatic prostate cancer[3]
BIND-014 is an Accurin nanomedicine produced by Bind Therapeutics Inc.[1] BIND-014 targets prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer cells and the blood vessels of many types of solid tumors, and contains docetaxel[1] as the cytotoxic agent.
Positive results in non-small cell lung cancer were presented in late 2014.[1]
Bind Therapeutics Inc. declared bankruptcy in 2017, halting development of the agent.[4]
References[edit]
- ↑ 1.0 1.1 1.2 1.3 BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium[dead link]
- ↑ A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2)
- ↑ A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
- ↑ "WTF Happened to Bind Therapeutics?". Nanalyze. 2017-08-01. Retrieved 2019-09-24.
 | This medical treatment–related article is a stub. You can help EverybodyWiki by expanding it. |
This article "BIND-014" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:BIND-014. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
